A Randomized, Triple-arm, Controlled, Open-label, Multicenter Phase II Study Assessing Two Different Doses of Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

Trial Profile

A Randomized, Triple-arm, Controlled, Open-label, Multicenter Phase II Study Assessing Two Different Doses of Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2016

At a glance

  • Drugs Panobinostat (Primary) ; Carfilzomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms PANORAMA-5
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 03 Oct 2016 Planned End Date changed from 1 Nov 2020 to 1 Feb 2021.
    • 03 Oct 2016 Planned primary completion date changed from 1 Nov 2020 to 1 Feb 2021.
    • 03 Oct 2016 Planned initiation date changed from 1 Jun 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top